English
Spanish
French
Italian
German
NEWS
Latest News
HS in Skin of Color: Bridging Gaps in Diagnosis, Treatment, and Equity
June 22, 2026
In this episode of Skin of Color Savvy, Tiffany Mayo, MD, Steven Daveluy, MD, and patient advocate Jasmine Ivanna Espy unpack the unique challenges of hidradenitis suppurativa (HS) in patients with skin of color, from delayed diagnosis to treatment hesitancy and access barriers. Blending clinical expertise with lived experience, the discussion highlights practical strategies to improve recognition, expand therapeutic confidence, and center patient voices in more equitable HS care.
Read more
The Emerging Role of Povorcitinib in Moderate to Severe Hidradenitis Suppurativa
June 16, 2026
A potential new chapter in hidradenitis suppurativa (HS) treatment is unfolding with povorcitinib, an oral JAK1-selective inhibitor showing promising phase 3 results. In patients with moderate to severe disease—many with prior biologic exposure—clinical response rates improved over time, alongside meaningful reductions in pain and draining tunnels. With generally favorable tolerability and the convenience of once-daily dosing, povorcitinib could help address persistent gaps in HS care and expand options beyond injectable biologics.
Read more
Expanding the HS Treatment Landscape: From Single-Pathway Therapy to Personalized Care
June 15, 2026
The hidradenitis suppurativa (HS) treatment landscape is evolving rapidly, with dozens of biologics and small-molecule therapies in development targeting multiple inflammatory pathways. In this interview, Leandra A. Barnes, MD, FAAD, discusses the shift toward more personalized, patient-centered care, the challenges of treatment dissatisfaction and access barriers, and the promise of emerging therapies that may help improve outcomes for people living with HS.
Read more
Q&A: How Does the Current HS Landscape Look? With Kiera Booth, MD
June 8, 2026
With new biologics expanding treatment options and additional therapies on the horizon, the hidradenitis suppurativa (HS) landscape is rapidly evolving. In this HCPLive Q&A, Kiera Booth, MD, discusses the importance of early diagnosis, individualized treatment selection, procedural approaches such as deroofing, and emerging therapies that may help improve outcomes for patients with HS.
Read more
Pediatric HS Insights: Colleen Cotton, MD, on Early Recognition, Referral, and Comprehensive Care
June 1, 2026
In this video series from Contemporary Pediatrics, Colleen Cotton, MD, FAAD, shares practical guidance on recognizing hidradenitis suppurativa (HS) in children and adolescents, identifying patients earlier through simple screening approaches, understanding key clinical signs, knowing when to refer, and supporting patients beyond medical treatment. These expert perspectives highlight opportunities to reduce diagnostic delays and improve outcomes for pediatric patients living with HS.
Read more
Advanced Antibiotic Strategies in Hidradenitis Suppurativa
May 22, 2026
In this Medscape podcast, expert clinicians discuss the real‑world challenges of caring for patients with hidradenitis suppurativa—covering timely diagnosis, evolving treatment strategies, and the importance of addressing quality‑of‑life burdens. The conversation offers practical insights to help clinicians improve outcomes and support patients over the long term.
Read more
Bimekizumab Shows Durable Responses in Psoriasis and HS Through 3 Years
May 18, 2026
New long‑term data presented at the 2026 AAD Annual Meeting suggest bimekizumab delivers durable disease control in hidradenitis suppurativa, with a growing proportion of patients remaining flare‑free through 3 years and no new safety signals observed. In this brief interview, Steven Daveluy, MD, discusses why extended assessment periods matter in HS, how sustained response influences treatment confidence, and what these findings may mean for long‑term patient care.
Read more
HS Care Has Outgrown Its Standards. The Field Is Catching Up.
May 18, 2026
HS care is evolving—and fast. This article with HS Foundation CEO, Brent Hazelett, explores how traditional standards are struggling to keep up with the realities of hidradenitis suppurativa, and why new, more patient-centered approaches are finally gaining traction. Discover what’s changing, what still needs improvement, and how the field is beginning to close the gap between outdated guidelines and real-world care.
Read more
Advancing Hidradenitis Suppurativa Care: Expert Perspectives on Diagnosis, Treatment, and Patient Impact
May 16, 2026
In this Dermatology Times video series, board-certified dermatologists Dr. Jennifer Hsiao and Dr. Barry Resnik take a comprehensive look at Hidradenitis Suppurativa—from the multidimensional burden and diagnostic challenges to evolving therapies like JAK inhibitors. Through expert insights and practical guidance, this series equips dermatologists to recognize HS earlier, address misconceptions, build patient trust, and improve long-term outcomes.
Read more
Hidradenitis Suppurativa Explained: From Pain and Stigma to Promising New Treatments
May 13, 2026
What exactly is Hidradenitis Suppurativa (HS), and why is it so often misunderstood? On this episode of Science of Skin, dermatologist Dr. Ted Lain and HS expert Dr. Steve Daveluy unpack the biology, burden, and breakthrough therapies shaping the future of HS care.
Read more